Evidence map›Paper›PMID 20727204›Full record

ArticleMolecular cancer2010

Musashi1 regulates breast tumor cell proliferation and is a prognostic indicator of poor survival.

Xiao-Yang Wang, Luiz Of Penalva, Hongyan Yuan, R Ilona Linnoila, Jiachun Lu, Hideyuki Okano, Robert I Glazer

Open access · goldAbstract read
In one paragraph

Article in Molecular cancer, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 89 papers.

0numbers the graph read from it
0cells of the map it votes in
89citing papers in PubMed
3.6field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

89 citing papers in PubMed, 136 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article

29 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 6 institutions in 3 countries.

Xiao-Yang WangDepartment of Oncology, Georgetown University, and Lombardi Comprehensive Cancer Center, Washington, DC 20007, USA. wangxiao@mail.nih.gov
Luiz Of Penalva
Hongyan Yuan
R Ilona Linnoila
Jiachun Lu
Hideyuki Okano
Robert I Glazer
Georgetown University Medical Center · USGeorgetown University · USKeio University · JPNational Institutes of Health · USState Key Laboratory of Respiratory Disease · CNThe University of Texas Health Science Center at San Antonio · US

Funding

NCI NIH HHS R01 CA11482
6 · The paper itself

Abstract

backgroundMusashi1 (Msi1) is a conserved RNA-binding protein that regulates the Notch and Wnt pathways, and serves as a stem cell marker in the breast and other tissues. It is unknown how Msi1 relates to other breast cancer markers, whether it denotes tumor initiating cells (TICs), and how it affects gene expression and tumor cell survival in breast cancer cells.

resultsMsi1 expression was analyzed in 20 breast cancer cell lines and in 140 primary breast tumors by western blotting and immunohistochemistry, respectively. Lentivirus RNA interference was used to reduce Msi1 expression in breast cancer cell lines MCF-7 and T47D grown as spheroid cultures and to assess stem cell gene expression and the growth of these cell lines as xenografts. In normal human breast tissue, Msi1 was expressed in 10.6% of myoepithelum and 1.2% of ductal epithelium in the terminal ductal lobular unit (TDLU), whereas, less than 0.05% of ductal epithelium and myoepithelium in large ducts outside the TDLU expressed Msi1. Msi1 was expressed in 55% of the breast cancer cell lines and correlated with ErbB2 expression in 50% of the cell lines. Msi1 was expressed in 68% of primary tumors and in 100% of lymph node metastases, and correlated with 5 year survival. Msi1 was enriched in CD133+ MCF-7 and T47D cells and in spheroid cultures of these cells, and Msi1 'knockdown' (KD) with a lentivirus-expressed shRNA decreased the number and size of spheroid colonies. Msi1 KD reduced Notch1, c-Myc, ErbB2 and pERK1/2 expression, and increased p21CIP1 expression, which is consistent with known Msi1 target mRNAs. Msi1 KD also reduced the expression of the somatic and embryonic stem cell markers, CD133, Bmi1, Sox2, Nanog and Oct4. Xenografts of MCF-7 and T47D Msi1 KD cells resulted in a marked reduction of tumor growth, reduced Msi1 and Notch1 expression and increased p21CIP1 expression.

conclusionMsi1 is a negative prognostic indicator of breast cancer patient survival, and is indicative of tumor cells with stem cell-like characteristics. Msi1 KD reduces tumor cell survival and tumor xenograft growth, suggesting that it may represent a novel target for drug discovery.

Indexed as

AC133 AntigenAnimalsAntigens, CDBlotting, WesternBreast NeoplasmsCell LineCell Line, TumorCell ProliferationErb-b2 Receptor Tyrosine KinasesFemaleFlow CytometryFluorescent Antibody TechniqueGlycoproteinsHumansImmunohistochemistryMiceAC133 AntigenAntigens, CDERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesGlycoproteinsMSI1 protein, humanNerve Tissue ProteinsNOTCH1 protein, humanPeptidesPROM1 protein, humanProm1 protein, mouseReceptor, Notch1RNA-Binding Proteins

Identifiers

PMID20727204
PMCPMC2939568
OpenAlexW2098016561

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.